Cargando…

P081: Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival

Detalles Bibliográficos
Autores principales:	Baech, Joachim, Jakobsen, Lasse Hjort, El-Galaly, Tarec Christoffer, Molin, Daniel, Glimelius, Ingrid, Entrop, Joshua P., Crowther, Michael J., Smedby, Karin E., Eloranta, Sandra, Weibull, Caroline E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Living Beyond Lymphoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642052/ http://dx.doi.org/10.1097/01.HS9.0000890892.40630.c3

Ejemplares similares

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
por: Entrop, Joshua P., et al.
Publicado: (2022)

P074: Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study
por: Rossetti, Sára, et al.
Publicado: (2022)

P076: Pneumococcal infection in splenectomised Hodgkin lymphoma patients: Do they pose a problem today and what is the best long-term strategy?
por: Björkholm, Magnus, et al.
Publicado: (2022)

P078: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
por: Stadtbaeumer, Nele, et al.
Publicado: (2022)

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
por: Shakir, Rebecca, et al.
Publicado: (2022)

P075: My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients
por: Kailainathan, Gajan, et al.
Publicado: (2022)

P072: Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma
por: Bates, Cherie, et al.
Publicado: (2022)

P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
por: Geurts, Yvonne M.G., et al.
Publicado: (2022)

P067: A pilot of lung cancer screening for survivors of Hodgkin lymphoma
por: Broadbent, Rachel, et al.
Publicado: (2022)

T064: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
por: Neppelenbroek, Suzanne I.M., et al.
Publicado: (2022)

P069: Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients
por: Chuzel, Chloé, et al.
Publicado: (2022)

P071: First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands
por: Lammers, Eline M.J., et al.
Publicado: (2022)

T066: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study
por: Dinan, Michaela, et al.
Publicado: (2022)

P079: PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians
por: Ramos-Cillan, Sergio, et al.
Publicado: (2022)

P068: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
por: Marková, Jana, et al.
Publicado: (2022)

P070: Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?
por: Nijdam, Annelies, et al.
Publicado: (2022)

P080: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment
por: Mieras, Adinda, et al.
Publicado: (2022)

Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
por: Joelsson, Joel, et al.
Publicado: (2022)

Late relapses in Hodgkin lymphoma – should we search for the needle in the haystack?
por: El‐Galaly, Tarec Christoffer, et al.
Publicado: (2022)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment
por: Jensen, Paw, et al.
Publicado: (2022)

P1225: SECONDARY PRIMARY MALIGNANCIES (SPM) AFTER HIGH-DOSE CHEMOTHERAPY (HDT) WITH AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY
por: Trab, T., et al.
Publicado: (2022)

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy
por: Baech, Joachim, et al.
Publicado: (2022)

Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study
por: Wästerlid, Tove, et al.
Publicado: (2020)

Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark
por: Jakobsen, Lasse Hjort, et al.
Publicado: (2022)

Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma
por: Pinnix, Chelsea C., et al.
Publicado: (2018)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Sex differences in lymphoma incidence and mortality by subtype: A population‐based study
por: Radkiewicz, Cecilia, et al.
Publicado: (2022)

P1093: A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED-STAGE HODGKIN LYMPHOMA.
por: Rask Kragh Jørgensen, R., et al.
Publicado: (2022)

PB2706: NO DIFFERENCE IN SURVIVAL OUTCOMES BETWEEN IMMIGRANTS AND DANISH-BORN CITIZENS WITH A HEMATOLOGICAL MALIGNANCY: A NATIONWIDE, POPULATION-BASED REGISTER STUDY
por: Baech, Joachim, et al.
Publicado: (2023)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2023)

Estimating the loss of lifetime function using flexible parametric relative survival models
por: Jakobsen, Lasse H., et al.
Publicado: (2019)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies
por: Boot, Max V., et al.
Publicado: (2022)

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rg2eb8jmt4nptdvbou6imhb4f8